USOR 25120 - Ph3 Sonesitatug vedotin + Fluoropyrimidine in Gastric, GEJ, or Esophageal Adeno (CLARITY-Gastric02)

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2 negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Disease Types: Gastric, Gastric/Gastroesophageal

Available at: Arlington Heights, Chicago, Niles